id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-346017-wforwxes	Kasperkiewicz, M.	Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic	2020-04-25		.txt	text/plain	649	27	26	Since immunosuppressive therapy can generally inhibit antiviral immunity, AIBD patients undergoing immunomodulatory treatment, especially elderly patients with co-morbidities, may be at higher risk of worse outcomes should they develop COVID-19. key: cord-346017-wforwxes authors: Kasperkiewicz, M.; Schmidt, E.; Fairley, J.A.; Joly, P.; Payne, A.S.; Yale, M.L.; Zillikens, D.; Woodley, D.T. title: Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic date: 2020-04-25 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.16525 sha: doc_id: 346017 cord_uid: wforwxes Autoimmune bullous diseases (AIBDs) are potentially life‐threatening disorders comprising intra‐epidermal/epithelial (pemphigus) and sub‐epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis).	cache/cord-346017-wforwxes.txt	txt/cord-346017-wforwxes.txt
